Comment k Defeats Design Defect Claims Asserted Against Serophene Maker, Ala. Federal Judge Rules



DOCUMENTS
  • Order


BIRMINGHAM, Ala. — An Alabama federal judge has held that design defect claims asserted against the maker of the fertility drug Serophene are barred by comment k of the Restatement (Second) of Torts, which limits the liability of prescription drug manufacturers.

However, in the March 21 order, Judge Madeline Haikala of the U.S. District Court for the Northern District of Alabama allowed the plaintiff’s failure-to-warn claims to proceed, ruling that at this stage of the proceedings, they are adequately pled.

From August 1993 through January 1994, Ashlye Barcal’s mother took Serophene (clomiphene citrate) to help her conceive, and became pregnant …

FIRM NAMES
  • Burr & Forman
  • Freese & Goss
  • Nixon Peabody
  • Wagstaff & Cartmell





UPCOMING CONFERENCES




HarrisMartin's Webinar Series: Video Game Addiction Product Liability Litigation

March 29, 2024

MORE DETAILS



HarrisMartin's MDL Conference: Video Game Addiction and the Latest Mass Tort Updates

May 29, 2024

MORE DETAILS